CMA issues over £100m in fines after 1,110% thyroid drug price hike

The CMA has slapped more than £100 million worth of fines on Advanz Pharma, HgCapital and Cinven after it concluded that the price of a thyroid drug was inflated by 1,110%.

CMA_0.jpg
Advanz Pharma and Cinven told C+D they will appeal the CMA’s decision

The outcome of a Competition and Markets Authority’s (CMA) investigation, published today (July 29), found that Advanz charged an excessive price for its liothyronine tablets, which are used to treat thyroid hormone deficiency.

Free to registered users

Register to gain full access to C+D and C+D Community content

Sign in or register for free

Latest from News

Sebco coal tar scalp ointment appointed by DHSC to support current shortages

 • comment

Due to shortages in coal tar scalp ointment, the DHSC has asked the manufacturer of an equivalent product - Sebco - to provide increased stock levels to support patients during this time.

Pharmacies to boost naloxone stock amid ‘sudden’ overdose spike

 
• By 
 • comment

Pharmacies in Scotland have been asked to ensure they have the “appropriate stock” of naloxone – a medicine used to reverse the effects of an opiate overdose – following an “increase in sudden collapse” due to overdoses.

Cuts and commissioning: What does NHSE’s axing mean for ICBs?

 
• By 
 • comment

As the dust settles on the announcement that NHS England (NHSE) is set for the scrapheap, questions on what a 50% headcount cut means for local commissioners remain…

More from